Gilead has several patent applications in India on lenacapavir. Two of these patent applications, filed in 2020, seek patents on the choline and sodium salt of the drug lenacapavir.
Researchers have long studied how a small percentage of infected individuals with HIV are able to make bnAbs. However, researchers have demonstrated that bnAbs can protect against the virus if they are present before a person gets infected.
Prior to infection, men who acquired HIV had elevated inflammatory cytokines and bioactive lipids, both of which are associated with systemic inflammation, indicating that their bodies were constantly on the defensive against infection or injury, according to the researchers.